- Home
- CLDI vs SYBX Comparison
CLDI vs SYBX Comparison
Compare CLDI & SYBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLDI
- SYBX
- Stock Information
- Founded
- CLDI 2014
- SYBX N/A
- Country
- CLDI United States
- SYBX United States
- Employees
- CLDI N/A
- SYBX N/A
- Industry
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- SYBX Biotechnology: Pharmaceutical Preparations
- Sector
- CLDI Health Care
- SYBX Health Care
- Exchange
- CLDI Nasdaq
- SYBX Nasdaq
- Market Cap
- CLDI 18.1M
- SYBX 17.0M
- IPO Year
- CLDI N/A
- SYBX N/A
- Fundamental
- Price
- CLDI $1.36
- SYBX $1.42
- Analyst Decision
- CLDI Strong Buy
- SYBX Hold
- Analyst Count
- CLDI 3
- SYBX 3
- Target Price
- CLDI $16.67
- SYBX $1.00
- AVG Volume (30 Days)
- CLDI 1.1M
- SYBX 74.6K
- Earning Date
- CLDI 11-12-2024
- SYBX 11-12-2024
- Dividend Yield
- CLDI N/A
- SYBX N/A
- EPS Growth
- CLDI N/A
- SYBX N/A
- EPS
- CLDI N/A
- SYBX N/A
- Revenue
- CLDI N/A
- SYBX $2,777,000.00
- Revenue This Year
- CLDI N/A
- SYBX N/A
- Revenue Next Year
- CLDI N/A
- SYBX N/A
- P/E Ratio
- CLDI N/A
- SYBX N/A
- Revenue Growth
- CLDI N/A
- SYBX 292.23
- 52 Week Low
- CLDI $0.14
- SYBX $1.22
- 52 Week High
- CLDI $3.89
- SYBX $5.12
- Technical
- Relative Strength Index (RSI)
- CLDI 35.60
- SYBX 48.54
- Support Level
- CLDI $1.60
- SYBX $1.36
- Resistance Level
- CLDI $2.17
- SYBX $1.88
- Average True Range (ATR)
- CLDI 0.20
- SYBX 0.09
- MACD
- CLDI -0.10
- SYBX -0.01
- Stochastic Oscillator
- CLDI 10.00
- SYBX 11.54
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical stage immuno-oncology company pioneering the development and commercialization of novel, potent and efficient stem cell-based platforms for delivery and potentiation of oncolytic viruses for the treatment of cancer.
About SYBX Synlogic Inc.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.